Home Supplements That Start With H Hydase: Subcutaneous Hydration Support, Drug Dispersion, Recommended Dosages, and Side Effects

Hydase: Subcutaneous Hydration Support, Drug Dispersion, Recommended Dosages, and Side Effects

24

Hydase is the brand name for hyaluronidase, an injectable enzyme used by clinicians to help fluids and medicines spread more evenly through subcutaneous tissue. By temporarily breaking down hyaluronic acid—the “gel” that holds cells together—Hydase lowers tissue viscosity so injected solutions absorb faster and more predictably. In practice, this makes subcutaneous hydration (hypodermoclysis) more efficient, supports dispersion of certain injected drugs, and can assist select diagnostic or surgical procedures when intravenous access is difficult. Modern formulations include animal-derived and recombinant human versions; your clinical team chooses based on setting, allergies, and availability. Though often described as a “spreading agent,” Hydase is a prescription medicine with specific indications, dosing, and precautions. Used correctly, it can reduce needle sticks, improve comfort, and save time—especially in pediatrics, geriatrics, oncology, and ophthalmology—while requiring careful attention to contraindications and drug compatibility.

Essential Insights

  • Facilitates rapid absorption and dispersion of subcutaneous fluids and co-injected drugs, improving comfort and predictability.
  • Typical add-on dose for drug dispersion: 50–300 Units, most commonly 150 Units, per injection solution; hypodermoclysis often uses 150 Units.
  • Not for IV use; avoid inflamed or infected sites and do not use to enhance dopamine or alpha-agonist drugs.
  • People with known hyaluronidase hypersensitivity (especially to animal-derived products) should avoid Hydase; consider recombinant forms when allergy risk is a concern.

Table of Contents

What is Hydase and how it works

Hydase (hyaluronidase) is an endoglycosidase—an enzyme that cleaves large sugar molecules. In connective tissue, the chief structural polysaccharide is hyaluronic acid (also called hyaluronan). Hyaluronic acid forms a hydrated, gel-like network that limits the spread of injected solutions and contributes to tissue turgor. Hydase temporarily depolymerizes hyaluronic acid by splitting glycosidic bonds, lowering the viscosity of the extracellular matrix for a short period (typically hours). During that window, fluids and co-injected medications distribute more widely through the subcutaneous space and are absorbed more rapidly into the lymphatic and capillary systems.

Because the effect is local and transient, Hydase acts as a facilitator rather than a treatment itself. Once the enzyme is cleared and tissues rebuild hyaluronic acid, normal barrier function returns. In practical terms, this means subcutaneous infusions flow with less resistance and without painful “lumps,” local anesthetics can reach their targets more uniformly, and certain diagnostic agents disperse adequately even when IV access is not feasible.

Formulations differ by source and protein structure:

  • Animal-derived (bovine or ovine) hyaluronidase: Longstanding options with broad clinical experience. They are effective but carry a small risk of hypersensitivity, particularly in sensitized individuals.
  • Recombinant human hyaluronidase: Produced in controlled systems to match the human enzyme’s sequence. It generally has a lower risk of immunogenic reactions and is widely used for subcutaneous hydration and as a dispersion adjuvant.

Hydase specifically denotes a bovine-derived hyaluronidase presentation. Regardless of brand, core pharmacology is shared: enhanced tissue permeability, faster dispersion and absorption, and dose-dependent effects. Clinically, the most visible benefits are reduced infusion site discomfort, fewer line restarts, smoother spread of local anesthesia, and improved reliability of subcutaneous therapy when IV routes are challenging (for example, in frail older adults, infants, or dehydrated patients with poor venous access).

Importantly, hyaluronidase is not a vasodilator and not a general antidote. It should not be given intravenously (the enzyme is rapidly inactivated in blood), and it must be used strategically with compatible solutions and drugs. When paired with local anesthetics, for example, hydase can hasten onset and improve spread but may shorten anesthetic duration and increase systemic uptake—factors clinicians weigh when selecting concentrations and volumes.

Back to top ↑

When is Hydase used in care

Hydase is used as an adjuvant—it supports another therapy’s delivery or performance. Common, well-established use cases include:

1) Subcutaneous fluid administration (hypodermoclysis).
When IV access is difficult or invasive, clinicians can deliver isotonic fluids through the subcutaneous route. Adding hyaluronidase reduces tissue resistance and allows comfortable administration at clinically meaningful rates. It is especially helpful in long-term care, palliative care, and pediatrics when gentle, sustained hydration is needed without repeated venipuncture. In neonates and young infants, careful rate and volume limits apply.

2) Enhancing the dispersion and absorption of injected drugs.
For certain subcutaneous or intramuscular injections, mixing Hydase into the solution helps the active drug distribute more uniformly and absorb more quickly. This may reduce injection-site reactions and improve the time to effect. The approach is drug-specific—providers confirm compatibility first and follow established doses (see dosing section).

3) Diagnostic adjuncts when IV access is not feasible.
Historically, hyaluronidase has been used to facilitate subcutaneous urography in select circumstances (e.g., infants with difficult venous access). While less common in modern practice, the indication remains described in labeling and is occasionally used in specialized contexts.

4) Ophthalmic regional anesthesia (adjunct).
In cataract and other eye surgeries that use regional blocks (peribulbar, retrobulbar, or sub-Tenon’s), small amounts of hyaluronidase added to the local anesthetic can improve the block’s spread and reduce injection-site pressure. Evidence over decades suggests it can speed onset and improve akinesia (immobility of the eye), though contemporary surgical techniques sometimes reduce the need for rapid, profound akinesia. Dosing in this setting is lower and expressed as Units per milliliter of local anesthetic, typically in the single- to low-double-digit Units/mL range chosen by the anesthesia team.

5) Management of select extravasations (off-label).
For non-vesicant and some irritant extravasations—such as certain hyperosmolar solutions and specific chemotherapeutic classes—clinicians may use hyaluronidase to promote dispersion and reduce tissue injury. Protocols often involve subdividing the dose into small intradermal or superficial subcutaneous injections around the infiltrated area and applying warm compresses to encourage dispersion. Not all extravasations are candidates (e.g., anthracyclines have different standards of care), so teams follow institutional algorithms.

6) Aesthetic and reconstructive situations (specialist use).
While Hydase is not labeled for dissolving cosmetic hyaluronic-acid fillers, hyaluronidase is widely used by qualified specialists for urgent management of vascular compromise from filler injections and for managing problematic filler nodules. Because allergy risk and dosing nuances differ across products and clinical contexts, this use is reserved for practitioners trained in oculoplastic, dermatologic, or plastic surgery emergency protocols.

Across settings, the thread is the same: Hydase improves tissue spread and uptake where the subcutaneous “gel” otherwise slows things down. Benefit is most pronounced when comfort, fewer needle sticks, and predictable absorption matter—and when professionals can control volume, rate, and compatibility to keep use safe.

Back to top ↑

How to dose Hydase correctly

Dosing is indication-specific and measured in Units (U) of hyaluronidase activity. Always follow the exact product label and your facility’s protocols. The ranges below reflect common, label-described practice patterns and widely used clinical protocols:

A) Enhancing dispersion of injected drugs (adjuvant).

  • Typical dose: 50–300 Units, most commonly 150 Units, added to the injection solution to facilitate dispersion and absorption.
  • When used with local anesthetics (e.g., soft-tissue infiltration): the add-on Units are often at the lower end of the range to balance spread with duration. Expect faster onset but potentially shorter duration due to increased systemic uptake.

B) Subcutaneous fluid administration (hypodermoclysis).

  • Common dose: 150 Units administered subcutaneously at or just before starting the infusion.
  • Effect: Facilitates absorption of ~1,000 mL or more of isotonic solution through a single site, depending on patient tolerance.
  • Pediatric limits: For premature infants or during the neonatal period, do not exceed 25 mL/kg/day total volume and keep the rate ≤ 2 mL/min. For infants and children under 3 years, limit a single clysis to ≤ 200 mL. Older patients should not exceed rates/volumes typically used for IV infusions.
  • Fluids: Use isotonic solutions unless otherwise directed; avoid hypotonic or strongly electrolyte-free solutions to reduce hypovolemia risk.

C) Subcutaneous urography (specialized).

  • Dose: 75 Units subcutaneously over each scapula, followed by administration of the contrast agent at the same sites when IV access cannot be achieved (primarily in infants/small children and select cases).

D) Ophthalmic regional anesthesia (adjunct; specialist).

  • Common practice: Add hyaluronidase to local anesthetic at ~7.5–15 U/mL (for example, 75 Units in 5 mL yields 15 U/mL) for peribulbar or retrobulbar blocks. Actual concentration is set by the anesthesia team based on block type, patient risk, and preference.
  • Expectation: Faster onset and improved spread; possible reduction in required anesthetic volume. Be mindful that increased spread can shorten anesthetic duration.

E) Extravasation management (off-label; follow protocol).

  • Typical bedside method: Inject ~150 Units total, divided into five small injections (~0.2–0.3 mL each) intradermally or superficially subcutaneously around the perimeter of the infiltrated area. Apply warm compresses as instructed.
  • Alternative dilute method: Some protocols use 15 U/mL solutions with similar five-injection patterns, especially in neonates and small infiltrations.
  • Timing: Best results when administered as early as possible after recognition of extravasation.
  • Important: Not all agents qualify; anthracyclines, vasopressors, and certain vesicants follow different antidotes or measures.

Preparation and handling essentials

  • Most presentations are single-use vials (e.g., 150 U/mL). Discard unused portions.
  • Do not administer IV. The enzyme is rapidly inactivated.
  • Storage: Refrigerate 2–8°C; do not freeze. Protect from light per label.
  • Compatibility: Confirm with reliable references before mixing. Known incompatibilities include furosemide, benzodiazepines, and phenytoin. Do not use Hydase to enhance absorption of dopamine or alpha-agonist drugs.

These dosing patterns are designed to deliver the enzyme where it works best—locally in the tissue matrix—while minimizing systemic exposure. Patient-specific factors (frailty, edema, infection risk, prior exposure/allergy) and the co-administered solution dictate the exact dose, site, and schedule chosen by clinicians.

Back to top ↑

Administration steps that really matter

Successful, comfortable use of Hydase depends as much on technique as on dose. The following step-wise approach reflects common, label-consistent practice with patient-safety priorities:

1) Confirm the indication and the product.
Verify that hyaluronidase is appropriate for the task (e.g., clysis facilitation, drug dispersion) and that the vial is the intended formulation (bovine/ovine vs recombinant human), concentration (commonly 150 U/mL), and within expiry. Check the patient’s allergy history; previous reactions to animal-derived hyaluronidase or sensitization increase risk. Follow any institutional skin-test procedures when required.

2) Choose site and prepare the field.
For subcutaneous uses, select a well-perfused area with adequate tissue (abdomen, thigh, upper arm, chest wall for scapular urography). Avoid inflamed, infected, irradiated, or edematous sites. Prep the skin using aseptic technique. In ophthalmic blocks and extravasation management, site selection and needle plane require specialist skill—these are not general ward procedures.

3) Plan the solution and check compatibility.
If you’re adding Hydase to another drug or local anesthetic, confirm chemical and physical compatibility from authoritative references before mixing. Remember the known incompatibilities (furosemide, benzodiazepines, phenytoin), and do not combine to enhance dopamine or alpha-agonist uptake. When using with local anesthetics, anticipate faster onset and potentially shorter duration; adjust anesthetic volume and monitoring accordingly.

4) Administer Hydase correctly.

  • Hypodermoclysis: Insert the clysis needle/cannula with the tip free in the subcutaneous plane. Begin the infusion and then inject 150 Units of hyaluronidase into the tubing near the site or pre-inject hydase subcutaneously at the site immediately before starting fluids. The infusion should flow easily without pain or a firm bleb.
  • Drug dispersion (co-injection): Add 50–300 Units (commonly 150 Units) to the prepared injection solution immediately before administration, observing aseptic technique.
  • Subcutaneous urography: Inject 75 Units subcutaneously over each scapula (patient prone) and then administer the contrast at the same sites.
  • Ophthalmic blocks: Dilute to the chosen Units/mL in the local anesthetic mix (often 7.5–15 U/mL) and inject using your block of choice (peribulbar, retrobulbar, sub-Tenon’s) with meticulous attention to orbital anatomy and pressure.
  • Extravasation (protocol-based): Mark the involved area. Using a fine needle, inject small aliquots around the perimeter (e.g., five × 0.2–0.3 mL totaling ~150 Units) and apply warm compresses per protocol. Document the agent, estimated volume extravasated, and the exact antidote steps taken.

5) Monitor response and comfort.
During clysis, inspect for easy flow and comfort. If a tense swelling or pain develops, pause and reassess cannula position, rate, or site selection. After extravasation treatment, reassess color, capillary refill, swelling, and pain at defined intervals. In ophthalmic care, monitor intraocular pressure and block characteristics; in all settings, observe for immediate hypersensitivity.

6) Educate and document.
Explain to patients and families that Hydase helps fluids or drugs spread and absorb, and that its effect is temporary. Document the product, lot number, dose, site, co-administered agents, and patient response—including any adverse effects.

7) Dispose appropriately.
Most vials are single-use; discard any remainder. Follow hazardous medication policies if the co-administered drug requires them.

Adherence to these steps minimizes complications and ensures the enzyme’s benefits—smooth flow, better dispersion, and fewer needle sticks—are achieved safely.

Back to top ↑

Risks, interactions, who should avoid

Hydase is generally well tolerated when used correctly, but it has specific contraindications, drug interactions, and adverse effects clinicians must know.

Contraindications and where not to use it

  • Known hypersensitivity to hyaluronidase or any component of the formulation. Animal-derived products carry a small but real risk of allergic reactions (e.g., urticaria, angioedema, rarely anaphylactoid events), especially in previously sensitized individuals. Consider recombinant human formulations when allergy risk is high.
  • Infected or acutely inflamed tissue. Enzymatic dispersion can spread localized infection; avoid injecting into cellulitis, abscesses, or irritated sites.
  • IV route. Do not administer intravenously; the enzyme is rapidly inactivated in blood and may cause unwanted systemic effects.
  • Bites and stings; corneal application. Do not use Hydase to reduce swelling from bites/stings and never apply directly to the cornea.

Adverse effects to watch for

  • Local reactions at the injection or infusion site: edema, erythema, tenderness, pruritus. Most are mild and transient.
  • Allergic reactions: rare but include urticaria, angioedema, bronchospasm, hypotension. Immediate treatment is required if they occur.
  • Systemic effects with local anesthetics: When added to local anesthetic solutions, hydase can increase systemic absorption, potentially shortening block duration and increasing the chance of systemic anesthetic effects if dosing is not adjusted appropriately.

Drug interactions and compatibility cautions

  • Incompatibilities: Furosemide, benzodiazepines, and phenytoin should not be mixed with hyaluronidase due to established incompatibility.
  • Do not enhance the absorption/dispersion of dopamine or alpha-agonists with hydase.
  • Local anesthetics: Faster onset and wider spread can be beneficial, but plan for shorter duration and consider dose adjustments.
  • Concomitant medications affecting tissue response: Large doses of salicylates, corticosteroids, ACTH, estrogens, or antihistamines may blunt hyaluronidase’s effect, occasionally requiring higher Units to achieve the same dispersion. Clinicians should interpret this in context and avoid routine “dose-creep.”

Special populations

  • Neonates and infants: Respect strict volume and rate limits during hypodermoclysis (≤ 25 mL/kg/day in neonates; rate ≤ 2 mL/min; single clysis ≤ 200 mL for children under 3 years). Closely monitor for over-hydration and electrolyte shifts.
  • Pregnancy and lactation: Use only if clearly needed. There are limited human data; no well-controlled reproductive studies exist.
  • Elderly/frail patients: Often derive significant benefit from clysis facilitation but require cautious fluid planning to avoid fluid overload.
  • Ophthalmic use: Reserve for skilled anesthesia providers; increased spread in the orbit, while often desirable, must be balanced against rare but serious block complications (e.g., retrobulbar hemorrhage).

Who should avoid Hydase or seek alternatives

  • Patients with documented hyaluronidase allergy (especially to animal-derived forms) unless a recombinant human product is deemed safe after appropriate assessment.
  • Patients with active soft-tissue infection at the planned site.
  • Situations where dispersion would worsen outcomes (e.g., keeping a local anesthetic contained for prolonged effect, or where a caustic extravasated agent requires specialized antidotes instead).

With thoughtful patient selection, compatibility checks, and route-specific technique, Hydase’s risk profile remains favorable—particularly compared with repeated or traumatic venipuncture attempts in vulnerable populations.

Back to top ↑

Evidence and alternatives at a glance

Mechanism and label evidence.
Core labeling across hyaluronidase products (including Hydase and recombinant human hyaluronidase) consistently documents the mechanism—temporary hydrolysis of hyaluronic acid—and indications for subcutaneous fluid administration, dispersion of injected drugs, and subcutaneous urography. Label dosing guidance establishes widely used reference points: 50–300 Units (usually 150 Units) for drug dispersion and 150 Units to facilitate ~1,000 mL of clysis solution. Contraindications (e.g., hypersensitivity), incompatibilities (furosemide, benzodiazepines, phenytoin), and cautions around alpha-agonists and dopamine are also stable across labels.

Ophthalmic anesthesia data.
Systematic and narrative reviews over many decades show that adding hyaluronidase to peribulbar or retrobulbar blocks can improve spread and speed of onset and may reduce anesthetic volume, with typical concentrations around 7.5–15 U/mL in the anesthetic mix. Some modern surgical workflows (e.g., small-incision cataract techniques) lessen the necessity of intense akinesia, so the incremental benefit can vary by practice. Safety concerns mainly relate to general block risks; allergic reactions to hyaluronidase are rare, and recombinant formulations may reduce immunogenicity.

Extravasation protocols.
Multidisciplinary guidance and practice reviews support hyaluronidase for select non-vesicant and irritant extravasations, especially hyperosmolar solutions and vinca alkaloids/taxanes, using small, subdivided injections (often five × 0.2–0.3 mL, totaling ~150 Units if using 150 U/mL) and warm compresses to encourage dispersion. Anthracycline extravasations are handled differently (e.g., cold compresses, specific antidotes like dexrazoxane). Timeliness is crucial—earlier intervention correlates with better outcomes.

What Hydase is not.
It is not itself a rehydration solution, antibiotic, anesthetic, or antidote for all extravasations. It won’t counter vasoconstrictive tissue injury (e.g., norepinephrine extravasation) and is not a general fix for injection-site pain without an underlying indication. It should never be given IV and never into infected tissue.

Alternatives and complements.

  • For hydration: oral rehydration (if feasible), IV lines, or multiple smaller SC sites without hyaluronidase.
  • For anesthesia spread: buffering local anesthetics, ultrasound-guided blocks, and volume titration strategies.
  • For extravasation: agent-specific antidotes (e.g., phentolamine for vasopressors, dimethyl sulfoxide or dexrazoxane per protocol), cold vs warm compresses, elevation, and surgical consults for severe cases.
  • For difficult access: ultrasound-guided IV cannulation, midlines, or PICCs may be preferred depending on clinical goals.

Bottom line.
Hydase’s value is pragmatic: it removes a physical barrier to tissue spread just long enough to do the job—hydrate comfortably, diffuse a drug evenly, or help a block perform reliably. In experienced hands and the right patients, it saves time, needle sticks, and discomfort, with a safety profile that is well understood and manageable.

Back to top ↑

References

Disclaimer

This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Hydase (hyaluronidase) is a prescription medication that must be used under qualified clinical supervision according to product labeling and institutional protocols. Always consult your physician, pharmacist, or anesthesia team for decisions about indications, dosing, compatibility, and site selection—especially for infants, pregnant or breastfeeding individuals, and people with allergy risks.

If you found this guide useful, please consider sharing it on Facebook, X (formerly Twitter), or your preferred platform, and follow us for future evidence-based articles. Your support helps us continue creating high-quality resources.

RELATED ARTICLESMORE FROM AUTHOR